1 Mycoplasma Hyopneumoniae Vaccine Market Overview 1.1 Product Overview and Scope of Mycoplasma Hyopneumoniae Vaccine 1.2 Mycoplasma Hyopneumoniae Vaccine Segment by Type 1.2.1 Global Mycoplasma Hyopneumoniae Vaccine Sales Growth Rate Comparison by Type (2021-2027) 1.2.2 Live 1.2.3 Inactivated 1.3 Mycoplasma Hyopneumoniae Vaccine Segment by Application 1.3.1 Global Mycoplasma Hyopneumoniae Vaccine Sales Comparison by Application: (2021-2027) 1.3.2 Piglets 1.3.3 Adult Pigs 1.4 Global Mycoplasma Hyopneumoniae Vaccine Market Size Estimates and Forecasts 1.4.1 Global Mycoplasma Hyopneumoniae Vaccine Revenue 2016-2027 1.4.2 Global Mycoplasma Hyopneumoniae Vaccine Sales 2016-2027 1.4.3 Mycoplasma Hyopneumoniae Vaccine Market Size by Region: 2016 Versus 2021 Versus 2027 2 Mycoplasma Hyopneumoniae Vaccine Market Competition by Manufacturers 2.1 Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Manufacturers (2016-2021) 2.2 Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Manufacturers (2016-2021) 2.3 Global Mycoplasma Hyopneumoniae Vaccine Average Price by Manufacturers (2016-2021) 2.4 Manufacturers Mycoplasma Hyopneumoniae Vaccine Manufacturing Sites, Area Served, Product Type 2.5 Mycoplasma Hyopneumoniae Vaccine Market Competitive Situation and Trends 2.5.1 Mycoplasma Hyopneumoniae Vaccine Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Mycoplasma Hyopneumoniae Vaccine Players Market Share by Revenue 2.5.3 Global Mycoplasma Hyopneumoniae Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Mycoplasma Hyopneumoniae Vaccine Retrospective Market Scenario by Region 3.1 Global Mycoplasma Hyopneumoniae Vaccine Retrospective Market Scenario in Sales by Region: 2016-2021 3.2 Global Mycoplasma Hyopneumoniae Vaccine Retrospective Market Scenario in Revenue by Region: 2016-2021 3.3 North America Mycoplasma Hyopneumoniae Vaccine Market Facts & Figures by Country 3.3.1 North America Mycoplasma Hyopneumoniae Vaccine Sales by Country 3.3.2 North America Mycoplasma Hyopneumoniae Vaccine Revenue by Country 3.3.3 United States 3.3.4 Canada 3.4 Europe Mycoplasma Hyopneumoniae Vaccine Market Facts & Figures by Country 3.4.1 Europe Mycoplasma Hyopneumoniae Vaccine Sales by Country 3.4.2 Europe Mycoplasma Hyopneumoniae Vaccine Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Mycoplasma Hyopneumoniae Vaccine Market Facts & Figures by Region 3.5.1 Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales by Region 3.5.2 Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 China Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.6 Latin America Mycoplasma Hyopneumoniae Vaccine Market Facts & Figures by Country 3.6.1 Latin America Mycoplasma Hyopneumoniae Vaccine Sales by Country 3.6.2 Latin America Mycoplasma Hyopneumoniae Vaccine Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.6.6 Colombia 3.7 Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Market Facts & Figures by Country 3.7.1 Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Sales by Country 3.7.2 Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 UAE 4 Global Mycoplasma Hyopneumoniae Vaccine Historic Market Analysis by Type 4.1 Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2016-2021) 4.2 Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2016-2021) 4.3 Global Mycoplasma Hyopneumoniae Vaccine Price by Type (2016-2021) 5 Global Mycoplasma Hyopneumoniae Vaccine Historic Market Analysis by Application 5.1 Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2016-2021) 5.2 Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2016-2021) 5.3 Global Mycoplasma Hyopneumoniae Vaccine Price by Application (2016-2021) 6 Key Companies Profiled 6.1 Zoetis 6.1.1 Zoetis Corporation Information 6.1.2 Zoetis Description and Business Overview 6.1.3 Zoetis Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2016-2021) 6.1.4 Zoetis Mycoplasma Hyopneumoniae Vaccine Product Portfolio 6.1.5 Zoetis Recent Developments/Updates 6.2 Merck 6.2.1 Merck Corporation Information 6.2.2 Merck Description and Business Overview 6.2.3 Merck Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2016-2021) 6.2.4 Merck Mycoplasma Hyopneumoniae Vaccine Product Portfolio 6.2.5 Merck Recent Developments/Updates 6.3 Boehringer Ingelheim 6.3.1 Boehringer Ingelheim Corporation Information 6.3.2 Boehringer Ingelheim Description and Business Overview 6.3.3 Boehringer Ingelheim Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2016-2021) 6.3.4 Boehringer Ingelheim Mycoplasma Hyopneumoniae Vaccine Product Portfolio 6.3.5 Boehringer Ingelheim Recent Developments/Updates 6.4 Ceva Santé Animale 6.4.1 Ceva Santé Animale Corporation Information 6.4.2 Ceva Santé Animale Description and Business Overview 6.4.3 Ceva Santé Animale Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Ceva Santé Animale Mycoplasma Hyopneumoniae Vaccine Product Portfolio 6.4.5 Ceva Santé Animale Recent Developments/Updates 6.5 Elanco Animal Health 6.5.1 Elanco Animal Health Corporation Information 6.5.2 Elanco Animal Health Description and Business Overview 6.5.3 Elanco Animal Health Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2016-2021) 6.5.4 Elanco Animal Health Mycoplasma Hyopneumoniae Vaccine Product Portfolio 6.5.5 Elanco Animal Health Recent Developments/Updates 6.6 Qilu Animal Health 6.6.1 Qilu Animal Health Corporation Information 6.6.2 Qilu Animal Health Description and Business Overview 6.6.3 Qilu Animal Health Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2016-2021) 6.6.4 Qilu Animal Health Mycoplasma Hyopneumoniae Vaccine Product Portfolio 6.6.5 Qilu Animal Health Recent Developments/Updates 6.7 Ruipu 6.6.1 Ruipu Corporation Information 6.6.2 Ruipu Description and Business Overview 6.6.3 Ruipu Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Ruipu Mycoplasma Hyopneumoniae Vaccine Product Portfolio 6.7.5 Ruipu Recent Developments/Updates 6.8 Shanghai Hile Bio-Technology Co., Ltd. 6.8.1 Shanghai Hile Bio-Technology Co., Ltd. Corporation Information 6.8.2 Shanghai Hile Bio-Technology Co., Ltd. Description and Business Overview 6.8.3 Shanghai Hile Bio-Technology Co., Ltd. Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2016-2021) 6.8.4 Shanghai Hile Bio-Technology Co., Ltd. Mycoplasma Hyopneumoniae Vaccine Product Portfolio 6.8.5 Shanghai Hile Bio-Technology Co., Ltd. Recent Developments/Updates 6.9 CAHIC 6.9.1 CAHIC Corporation Information 6.9.2 CAHIC Description and Business Overview 6.9.3 CAHIC Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2016-2021) 6.9.4 CAHIC Mycoplasma Hyopneumoniae Vaccine Product Portfolio 6.9.5 CAHIC Recent Developments/Updates 6.10 Pulike 6.10.1 Pulike Corporation Information 6.10.2 Pulike Description and Business Overview 6.10.3 Pulike Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2016-2021) 6.10.4 Pulike Mycoplasma Hyopneumoniae Vaccine Product Portfolio 6.10.5 Pulike Recent Developments/Updates 6.11 Harbin Pharmaceutical Group 6.11.1 Harbin Pharmaceutical Group Corporation Information 6.11.2 Harbin Pharmaceutical Group Mycoplasma Hyopneumoniae Vaccine Description and Business Overview 6.11.3 Harbin Pharmaceutical Group Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2016-2021) 6.11.4 Harbin Pharmaceutical Group Mycoplasma Hyopneumoniae Vaccine Product Portfolio 6.11.5 Harbin Pharmaceutical Group Recent Developments/Updates 7 Mycoplasma Hyopneumoniae Vaccine Manufacturing Cost Analysis 7.1 Mycoplasma Hyopneumoniae Vaccine Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Mycoplasma Hyopneumoniae Vaccine 7.4 Mycoplasma Hyopneumoniae Vaccine Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Mycoplasma Hyopneumoniae Vaccine Distributors List 8.3 Mycoplasma Hyopneumoniae Vaccine Customers 9 Mycoplasma Hyopneumoniae Vaccine Market Dynamics 9.1 Mycoplasma Hyopneumoniae Vaccine Industry Trends 9.2 Mycoplasma Hyopneumoniae Vaccine Growth Drivers 9.3 Mycoplasma Hyopneumoniae Vaccine Market Challenges 9.4 Mycoplasma Hyopneumoniae Vaccine Market Restraints 10 Global Market Forecast 10.1 Mycoplasma Hyopneumoniae Vaccine Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Mycoplasma Hyopneumoniae Vaccine by Type (2022-2027) 10.1.2 Global Forecasted Revenue of Mycoplasma Hyopneumoniae Vaccine by Type (2022-2027) 10.2 Mycoplasma Hyopneumoniae Vaccine Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Mycoplasma Hyopneumoniae Vaccine by Application (2022-2027) 10.2.2 Global Forecasted Revenue of Mycoplasma Hyopneumoniae Vaccine by Application (2022-2027) 10.3 Mycoplasma Hyopneumoniae Vaccine Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Mycoplasma Hyopneumoniae Vaccine by Region (2022-2027) 10.3.2 Global Forecasted Revenue of Mycoplasma Hyopneumoniae Vaccine by Region (2022-2027) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Mycoplasma Hyopneumoniae Vaccine Sales (K Units) Growth Rate Comparison by Type (2021-2027) Table 2. Global Mycoplasma Hyopneumoniae Vaccine Sales (K Units) Comparison by Application (2021-2027) Table 3. Global Mycoplasma Hyopneumoniae Vaccine Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers Mycoplasma Hyopneumoniae Vaccine Covered in This Study Table 5. Global Mycoplasma Hyopneumoniae Vaccine Sales (K Units) of Key Manufacturers (2016-2021) Table 6. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Manufacturers (2016-2021) Table 7. Global Mycoplasma Hyopneumoniae Vaccine Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global Mycoplasma Hyopneumoniae Vaccine Revenue Share by Manufacturers (2016-2021) Table 9. Global Market Mycoplasma Hyopneumoniae Vaccine Average Price (US$/Unit) of Key Manufacturers (2016-2021) Table 10. Manufacturers Mycoplasma Hyopneumoniae Vaccine Manufacturing Sites and Area Served Table 11. Manufacturers Mycoplasma Hyopneumoniae Vaccine Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Mycoplasma Hyopneumoniae Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Mycoplasma Hyopneumoniae Vaccine as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Mycoplasma Hyopneumoniae Vaccine Sales by Region (2016-2021) & (K Units) Table 16. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region (2016-2021) Table 17. Global Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2016-2021) & (US$ Million) Table 18. North America Mycoplasma Hyopneumoniae Vaccine Sales by Country (2016-2021) & (K Units) Table 19. North America Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2016-2021) Table 20. North America Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2016-2021) & (US$ Million) Table 21. North America Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2016-2021) Table 22. Europe Mycoplasma Hyopneumoniae Vaccine Sales by Country (2016-2021) & (K Units) Table 23. Europe Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2016-2021) Table 24. Europe Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales by Region (2016-2021) & (K Units) Table 27. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region (2016-2021) Table 28. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Region (2016-2021) Table 30. Latin America Mycoplasma Hyopneumoniae Vaccine Sales by Country (2016-2021) & (K Units) Table 31. Latin America Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2016-2021) Table 32. Latin America Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Sales by Country (2016-2021) & (K Units) Table 35. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2016-2021) Table 38. Global Mycoplasma Hyopneumoniae Vaccine Sales (K Units) by Type (2016-2021) Table 39. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2016-2021) Table 40. Global Mycoplasma Hyopneumoniae Vaccine Revenue (Million US$) by Type (2016-2021) Table 41. Global Mycoplasma Hyopneumoniae Vaccine Revenue Share by Type (2016-2021) Table 42. Global Mycoplasma Hyopneumoniae Vaccine Price (US$/Unit) by Type (2016-2021) Table 43. Global Mycoplasma Hyopneumoniae Vaccine Sales (K Units) by Application (2016-2021) Table 44. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2016-2021) Table 45. Global Mycoplasma Hyopneumoniae Vaccine Revenue (Million US$) by Application (2016-2021) Table 46. Global Mycoplasma Hyopneumoniae Vaccine Revenue Share by Application (2016-2021) Table 47. Global Mycoplasma Hyopneumoniae Vaccine Price (US$/Unit) by Application (2016-2021) Table 48. Zoetis Corporation Information Table 49. Zoetis Description and Business Overview Table 50. Zoetis Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 51. Zoetis Mycoplasma Hyopneumoniae Vaccine Product Table 52. Zoetis Recent Developments/Updates Table 53. Merck Corporation Information Table 54. Merck Description and Business Overview Table 55. Merck Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 56. Merck Mycoplasma Hyopneumoniae Vaccine Product Table 57. Merck Recent Developments/Updates Table 58. Boehringer Ingelheim Corporation Information Table 59. Boehringer Ingelheim Description and Business Overview Table 60. Boehringer Ingelheim Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 61. Boehringer Ingelheim Mycoplasma Hyopneumoniae Vaccine Product Table 62. Boehringer Ingelheim Recent Developments/Updates Table 63. Ceva Santé Animale Corporation Information Table 64. Ceva Santé Animale Description and Business Overview Table 65. Ceva Santé Animale Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 66. Ceva Santé Animale Mycoplasma Hyopneumoniae Vaccine Product Table 67. Ceva Santé Animale Recent Developments/Updates Table 68. Elanco Animal Health Corporation Information Table 69. Elanco Animal Health Description and Business Overview Table 70. Elanco Animal Health Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 71. Elanco Animal Health Mycoplasma Hyopneumoniae Vaccine Product Table 72. Elanco Animal Health Recent Developments/Updates Table 73. Qilu Animal Health Corporation Information Table 74. Qilu Animal Health Description and Business Overview Table 75. Qilu Animal Health Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 76. Qilu Animal Health Mycoplasma Hyopneumoniae Vaccine Product Table 77. Qilu Animal Health Recent Developments/Updates Table 78. Ruipu Corporation Information Table 79. Ruipu Description and Business Overview Table 80. Ruipu Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 81. Ruipu Mycoplasma Hyopneumoniae Vaccine Product Table 82. Ruipu Recent Developments/Updates Table 83. Shanghai Hile Bio-Technology Co., Ltd. Corporation Information Table 84. Shanghai Hile Bio-Technology Co., Ltd. Description and Business Overview Table 85. Shanghai Hile Bio-Technology Co., Ltd. Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 86. Shanghai Hile Bio-Technology Co., Ltd. Mycoplasma Hyopneumoniae Vaccine Product Table 87. Shanghai Hile Bio-Technology Co., Ltd. Recent Developments/Updates Table 88. CAHIC Corporation Information Table 89. CAHIC Description and Business Overview Table 90. CAHIC Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 91. CAHIC Mycoplasma Hyopneumoniae Vaccine Product Table 92. CAHIC Recent Developments/Updates Table 93. Pulike Corporation Information Table 94. Pulike Description and Business Overview Table 95. Pulike Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 96. Pulike Mycoplasma Hyopneumoniae Vaccine Product Table 97. Pulike Recent Developments/Updates Table 98. Harbin Pharmaceutical Group Corporation Information Table 99. Harbin Pharmaceutical Group Description and Business Overview Table 100. Harbin Pharmaceutical Group Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 101. Harbin Pharmaceutical Group Mycoplasma Hyopneumoniae Vaccine Product Table 102. Harbin Pharmaceutical Group Recent Developments/Updates Table 103. Production Base and Market Concentration Rate of Raw Material Table 104. Key Suppliers of Raw Materials Table 105. Mycoplasma Hyopneumoniae Vaccine Distributors List Table 106. Mycoplasma Hyopneumoniae Vaccine Customers List Table 107. Mycoplasma Hyopneumoniae Vaccine Market Trends Table 108. Mycoplasma Hyopneumoniae Vaccine Growth Drivers Table 109. Mycoplasma Hyopneumoniae Vaccine Market Challenges Table 110. Mycoplasma Hyopneumoniae Vaccine Market Restraints Table 111. Global Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Type (2022-2027) & (K Units) Table 112. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share Forecast by Type (2022-2027) Table 113. Global Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Type (2022-2027) & (US$ Million) Table 114. Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share Forecast by Type (2022-2027) Table 115. Global Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Application (2022-2027) & (K Units) Table 116. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share Forecast by Application (2022-2027) Table 117. Global Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Application (2022-2027) & (US$ Million) Table 118. Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share Forecast by Application (2022-2027) Table 119. Global Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Region (2022-2027) & (K Units) Table 120. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share Forecast by Region (2022-2027) Table 121. Global Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Region (2022-2027) & (US$ Million) Table 122. Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share Forecast by Region (2022-2027) Table 123. Research Programs/Design for This Report Table 124. Key Data Information from Secondary Sources Table 125. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Mycoplasma Hyopneumoniae Vaccine Figure 2. Global Mycoplasma Hyopneumoniae Vaccine Market Share by Type in 2020 & 2027 Figure 3. Live Product Picture Figure 4. Inactivated Product Picture Figure 5. Global Mycoplasma Hyopneumoniae Vaccine Market Share by Application in 2020 & 2027 Figure 6. Piglets Figure 7. Adult Pigs Figure 8. Global Mycoplasma Hyopneumoniae Vaccine Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 9. Global Mycoplasma Hyopneumoniae Vaccine Market Size 2016-2027 (US$ Million) Figure 10. Global Mycoplasma Hyopneumoniae Vaccine Sales 2016-2027 (K Units) Figure 11. Global Mycoplasma Hyopneumoniae Vaccine Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 12. Mycoplasma Hyopneumoniae Vaccine Sales Share by Manufacturers in 2020 Figure 13. Global Mycoplasma Hyopneumoniae Vaccine Revenue Share by Manufacturers in 2020 Figure 14. The Global 5 and 10 Largest Mycoplasma Hyopneumoniae Vaccine Players: Market Share by Revenue in 2020 Figure 15. Mycoplasma Hyopneumoniae Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 16. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region (2016-2021) Figure 17. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region in 2020 Figure 18. Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Region (2016-2021) Figure 19. Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Region in 2020 Figure 20. United States Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 21. Canada Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 22. Germany Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 23. France Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 24. U.K. Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 25. Italy Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 26. Russia Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. China Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. Japan Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. South Korea Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. India Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. Australia Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. China Taiwan Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. Indonesia Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. Thailand Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. Malaysia Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. Mexico Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Brazil Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Argentina Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Colombia Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Turkey Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Saudi Arabia Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. UAE Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Sales Market Share of Mycoplasma Hyopneumoniae Vaccine by Type (2016-2021) Figure 44. Sales Market Share of Mycoplasma Hyopneumoniae Vaccine by Application (2016-2021) Figure 45. Sales Market Share of Mycoplasma Hyopneumoniae Vaccine by Application in 2020 Figure 46. Revenue Share of Mycoplasma Hyopneumoniae Vaccine by Application (2016-2021) Figure 47. Revenue Share of Mycoplasma Hyopneumoniae Vaccine by Application in 2020 Figure 48. Manufacturing Cost Structure of Mycoplasma Hyopneumoniae Vaccine Figure 49. Manufacturing Process Analysis of Mycoplasma Hyopneumoniae Vaccine Figure 50. Mycoplasma Hyopneumoniae Vaccine Industrial Chain Analysis Figure 51. Channels of Distribution Figure 52. Distributors Profiles Figure 53. Bottom-up and Top-down Approaches for This Report Figure 54. Data Triangulation Figure 55. Key Executives Interviewed

Zoetis Merck Boehringer Ingelheim Ceva Santé Animale Elanco Animal Health Qilu Animal Health Ruipu Shanghai Hile Bio-Technology Co., Ltd. CAHIC Pulike Harbin Pharmaceutical Group